SEC Form 4 · accession 0001562180-19-000492
Sage Therapeutics, Inc. · SAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James M Frates
Director
Period of report
Jan 23, 2019
Accepted (ET)
Jan 24, 2019 · 5:44 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001597553
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 23, 2019 | M | 7,500 | $8.92 | A | 11,735 | D | |
| Common Stock | Jan 23, 2019 | S | 7,500 | $134.81 | D | 4,235 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $8.92 | Jan 23, 2019 | M | 7,500 | D | — | May 21, 2024 | Common Stock | 7,500 | 9,309 | D |
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- F2The shares subject to the option vested 33% on the first anniversary of the grant date and quarterly thereafter, such that 100% of the shares subject to the option were fully vested and exercisable on May 26, 2017.